Distribution Rights for Bleeding-Control Device

By HospiMedica staff writers
Posted on 20 Sep 2002

Exclusive rights to distribute a new device for the rapid control of bleeding have been granted to Medtronic, Inc. (Minneapolis, MN, USA) by Scion Cardio-Vascular, Inc. (Miami, FL, USA). Medtronic has made a minority investment in the company.

The device, called Clo-Sur PAD, is designed for rapid control of bleeding associated with all vascular access sites. However, the agreement with Medtronic is limited to the use of the device for bleeding associated with catheter removal following a catheterization procedure, such as angioplasty or coronary stenting. The device has been cleared by the US Food and Drug Administration (FDA).

"In our experience with over 1,000 Clo-Sur PADs, the device has proven to be safe, effective, and easy to use, and most important, it is noninvasive,” said Barry Alter, M.D., of Memorial Regional Hospital (Hollywood, FL, USA).

Related Links:
Medtronic, Inc.
Scion Cardio-Vascular, Inc